NeuroMetrix: Jumps after nerve stimulation device chosen for NIH-funded study

NeuroMetrix

16/04/2020 19:14

** Shares of medical device maker NeuroMetrix Inc  NURO.O 
rise 17.7% to $3.92
    ** Co's nerve stimulation device, Quell, is selected for use
in a large, National Institutes of Health (NIH)-funded clinical
trial of fibromyalgia  urn:newsml:reuters.com:*:nGNX2vhRwP
    ** Trial will assess the feasibility of using electrical
nerve stimulation in addition to physical therapy for treatment
of patients with fibromyalgia
    ** Fibromyalgia is a disorder characterized by widespread
musculoskeletal pain accompanied by fatigue, sleep, memory and
mood issues
    ** Quell stimulates sensory nerves with electrical pulses to
trigger a natural pain relief response
    ** Including session's gain, shares have fallen ~8.8% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))